SUZHOU, China, March 20, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC). This milestone brings another innovative bispecific ADC from the company's pipeline into pivotal development, reinforcing its potential to offer a more effective and safer treatment option for patients with TNBC. Breast cancer is the most commonly diagnosed malignancy among women worldwide, with a growing disease burden. TNBC accounts for approximately 15-20% of all breast cancer cases and…